The new and evolving pharmacotherapy of XXXX .

@entity1 @entity1088 @entity308 @entity161 @entity14867 @entity1037 @entity1089 @entity1090
Based on the evidence presented here, the following tentative conclusions can be drawn. Atypical antipsychotics (except amisulpride) have shown superiority over placebo in acute @entity161 . Compared with conventional antipsychotics, they are at least as effective. Generally, analyses employing conservative criteria (e.g., Cochrane reviews) report few efficacy differences between atypical and conventional agents. There are now many well-controlled studies indicating modest advantages for the atypical antipsychotics, however, particularly in specific symptom domains. For the treatment of negative symptoms, @entity1037 and to a lesser extent @entity14867 seem most promising. @entity1090 , @entity1037 , and @entity1089 display advantages in improving cognitive and @entity308 . There are indications that the atypical antipsychotics are associated with decreased likelihood of rehospitalization and improved quality of life. In head-to-head comparisons of atypical antipsychotics, none have shown consistent efficacy advantages. In severely refractory samples, no atypical antipsychotics have consistently been shown to be as effective as @entity1088 or superior to conventional agents. There are indications, however, that @entity1090 , @entity1037 , and @entity1089 have advantages over conventional agents in less severely refractory @entity1 . Few maintenance RCTs have been published, and efficacy advantages for atypical antipsychotics in prospective RCTs in first-episode @entity161 have not been reported.
